CLDI

Calidi Biotherapeutics, Inc. (CLDI) 10Y Growth Potential Analysis (2026)

Invetso Score: 2.6/10 — Weak · Last Updated: 2026-09-01

Monthly Update

No material changes this month.

Revenue Growth Drivers

Score: 2.8 (Weak)

Revenue growth visibility is limited because FMP provides no 5-year CAGR data, while negative ROIC suggests prior capital deployment has not yet translated into scalable sales expansion.

Low net debt reduces financing pressure, but peer-relative growth capacity remains weak because leverage alone does not create repeatable revenue compounding.

Near-zero capex intensity may preserve cash, yet it also implies limited reinvestment into expansion versus peers with clearer growth reinvestment pipelines.

The absence of disclosed segment concentration metrics makes durable cross-sell or multi-engine growth harder to evidence than for diversified peers.

Market Tailwinds

Score:

No filing-based evidence shows CLDI benefiting from a structural demand tailwind that would support multi-year revenue compounding versus stronger peer growth platforms.

Negative interest coverage indicates current operating economics are not yet aligned with sustained expansion, which weakens the ability to convert market demand into growth.

The available metrics do not show a differentiated addressable-market capture rate, leaving CLDI behind peers with proven share gains and recurring expansion.

Without segment or geographic growth disclosure, the company’s market expansion path remains less visible than peers with clearer end-market momentum.

Scalability Expansion

Score:

Negative ROIC and absent CAGR history indicate reinvested capital has not yet produced scalable returns, which caps long-term compounding versus peers.

Very low capex and R&D intensity suggest limited internal scaling investment, reducing the likelihood of sustained product or capacity expansion.

The extremely negative cash conversion cycle may reflect working-capital distortions, but it also signals operational complexity that can hinder scalable growth execution.

Compared with peers that show positive reinvestment flywheels, CLDI currently lacks evidence of a self-funding expansion model.

Constraints Limitations

Score:

Negative ROIC is the clearest structural constraint because it implies incremental capital has not been compounding revenue efficiently over time.

Negative interest coverage limits financial flexibility, making long-horizon expansion more difficult than for peers with stronger earnings support.

Missing 5-year growth and segment data reduces confidence in durable scaling, because the company cannot yet demonstrate repeatable expansion across cycles.

The current profile looks structurally constrained rather than mature, since the available metrics show limited evidence of a proven growth engine.

Overall Score

Score:

CLDI’s long-term growth capacity appears structurally constrained because the available metrics show negative ROIC, weak coverage, and little evidence of scalable reinvestment-driven revenue compounding versus peers.

Score Driver: Negative Roic

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Calidi Biotherapeutics, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →